Kristin Klemmetsby Solli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kristin Klemmetsby Solli has a total of 123 co-authors. Here are the top co-authors by number of shared publications:
Lars Tanum
15 shared publications- Bente Weimand
Mental Health Services, Akershus University Hospital, 1478 Nordbyhagen, Norway
8 shared publications Jūratė Šaltytė Benth
Institute of Clinical Medicine, Campus Ahus, University of Oslo, Oslo, Norway; Health Services Research Unit, Akershus University Hospital, Loerenskog, Norway
7 shared publications- Nikolaj Kunøe
Norwegian Center for Addiction Research, University of Oslo, Oslo, Norway
7 shared publications Arild Opheim
Department of Addiction Medicine, Haukeland University Hospital, Bergen, Norway
6 shared publicationsJon Mordal
5 shared publications
Latest Publications
- Open Access
- 11 February 2026
- Published by Elsevier in Journal of Affective Disorders Reports
- Vol. 24
Depression trajectories amongst individuals with opioid use disorder treated with extended-release naltrexone during 52-weeks, followed by a 52-week post-treatment period
- 11 February 2026
- Published by Elsevier in Journal of Affective Disorders Reports
- Vol. 24
Open AccessDepression trajectories amongst individuals with opioid use disorder treated with extended-release naltrexone during 52-weeks, followed by a 52-week post-treatment period
- Open Access
- 24 December 2025
- Published by MDPI AG in Brain Sciences
- Vol. 16 (1) , 23
Genetic Influence on Extended-Release Naltrexone Treatment Outcomes in Patients with Opioid Use Disorder: An Exploratory Study
Background/Objectives: The variation in the treatment outcomes of extended-release naltrexone (XR-NTX) including the potential role of genetic factors are poorly understood. This study aimed to explore the potential association between the catechol-O-methyltransferase (COMT) rs4680 and mu-opioid receptor (OPRM1) rs1799971 genotypes and XR-NTX treatment outcomes in patients with opioid use disorder (OUD) specifically focusing on treatment retention, relapse to opioids, number of days of opioid use, and opioid cravings. Methods: This was a 24-week, open-label clinical prospective, exploratory study involving patients with OUD who chose treatment with monthly injections of intramuscular XR-NTX. Men and women aged 18–65 years with OUD according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, were included. The participants were interviewed using the European Addiction Severity Index. Survival analyses and linear mixed models were used to analyze the data. Results: Of the 162 participants included in this study, 138 (21% female) initiated treatment with XR-NTX, with 88 genotyped for COMT rs4680 and 86 for OPRM1 rs1799971. Heterozygous Met/Val carriers of COMT rs4680 were less likely to relapse to opioids compared with those with the COMT rs4680 Met/Met genotype. No significant association was observed for the OPRM1 polymorphism. Conclusions: Patients with the COMT rs4680 Met/Val genotype exhibit a reduced risk of relapse to opioids and may therefore derive greater benefit from XR-NTX treatment compared with those with the COMT rs4680 Met/Met genotype. Future studies should be conducted with a larger number of participants and possibly include other genetic variants and treatment outcomes. The trial is registered at ClinicalTrials.gov (#NCT03647774) and the EU Clinical Trial Register (#2017-004706-18).
- 24 December 2025
- Published by MDPI AG in Brain Sciences
- Vol. 16 (1) , 23
Open AccessGenetic Influence on Extended-Release Naltrexone Treatment Outcomes in Patients with Opioid Use Disorder: An Exploratory Study
Background/Objectives: The variation in the treatment outcomes of extended-release naltrexone (XR-NTX) including the potential role of genetic factors are poorly understood. This study aimed to explore the potential association between the catechol-O-methyltransferase (COMT) rs4680 and mu-opioid receptor (OPRM1) rs1799971 genotypes and XR-NTX treatment outcomes in patients with opioid use disorder (OUD) specifically focusing on treatment retention, relapse to opioids, number of days of opioid use, and opioid cravings. Methods: This was a 24-week, open-label clinical prospective, exploratory study involving patients with OUD who chose treatment with monthly injections of intramuscular XR-NTX. Men and women aged 18–65 years with OUD according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, were included. The participants were interviewed using the European Addiction Severity Index. Survival analyses and linear mixed models were used to analyze the data. Results: Of the 162 participants included in this study, 138 (21% female) initiated treatment with XR-NTX, with 88 genotyped for COMT rs4680 and 86 for OPRM1 rs1799971. Heterozygous Met/Val carriers of COMT rs4680 were less likely to relapse to opioids compared with those with the COMT rs4680 Met/Met genotype. No significant association was observed for the OPRM1 polymorphism. Conclusions: Patients with the COMT rs4680 Met/Val genotype exhibit a reduced risk of relapse to opioids and may therefore derive greater benefit from XR-NTX treatment compared with those with the COMT rs4680 Met/Met genotype. Future studies should be conducted with a larger number of participants and possibly include other genetic variants and treatment outcomes. The trial is registered at ClinicalTrials.gov (#NCT03647774) and the EU Clinical Trial Register (#2017-004706-18).
- Open Access
- 24 December 2025
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 14, e67663
Chronic Pain and Posttraumatic Stress Among Patients in Substance Use Treatment: Protocol for NOR-APT, a Longitudinal Cohort Study
Background: Chronic pain conditions and posttraumatic stress disorder (PTSD) are highly prevalent among patients with substance use disorders (SUDs). Both can impact outcomes of SUD treatment and quality of life. There is a need for a large-scale study on the overlap of and interactions between SUD, chronic pain, and PTSD. Objective: The Norwegian Addiction, Pain and Trauma study (NOR-APT) is the first longitudinal study to describe how substance use and outcomes of SUD treatment are impacted by (1) chronic pain and pain characteristics and (2) interactions between comorbid chronic pain and PTSD. Methods: Self-reported questionnaire data were collected from patients in all types of SUD treatment at four hospital sites in Norway. The questionnaire data on substance use, pain, and posttraumatic stress symptoms will be combined with retrospective and prospective longitudinal data from high-quality demographic and health registries. The registry data cover, for example, treatment episodes, diagnoses, and prescribed medications and socioeconomic variables, with a follow-up period of altogether 20 years (approximately 2008-2029). Results: Questionnaire data were collected during March 2021-June 2024. Altogether 1890 patients were approached, and 1645 (87%) questionnaires were completed. The estimated final sample size pending data cleaning (eg, removal of duplicates and validation of consent forms) is 1400-1500. Linkage of registry data for approximately 1000 with valid ID numbers and consent is planned for 2026 (retrospective) and 2029/2030 (prospective). At least 10 publications are planned in the period 2025-2028, based on funding received from the Foundation Dam, the Norwegian Research Council, Akershus University Hospital, and Oslo University Hospital. We plan to apply for further funding related to the use of the prospective registry data. Conclusions: Results from the NOR-APT study will contribute to a better understanding of SUD, chronic pain and PTSD comorbidities, their interactions, trajectories and impact on SUD treatment outcomes, and subjective quality of life. Results can also contribute knowledge toward the development and assessment of treatment interventions that can improve SUD treatment outcomes. Trial Registration: ClinicalTrials.gov NCT04908410; https://clinicaltrials.gov/study/NCT04908410 International Registered Report Identifier (IRRID): DERR1-10.2196/67663
- 24 December 2025
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 14, e67663
Open AccessChronic Pain and Posttraumatic Stress Among Patients in Substance Use Treatment: Protocol for NOR-APT, a Longitudinal Cohort Study
Background: Chronic pain conditions and posttraumatic stress disorder (PTSD) are highly prevalent among patients with substance use disorders (SUDs). Both can impact outcomes of SUD treatment and quality of life. There is a need for a large-scale study on the overlap of and interactions between SUD, chronic pain, and PTSD. Objective: The Norwegian Addiction, Pain and Trauma study (NOR-APT) is the first longitudinal study to describe how substance use and outcomes of SUD treatment are impacted by (1) chronic pain and pain characteristics and (2) interactions between comorbid chronic pain and PTSD. Methods: Self-reported questionnaire data were collected from patients in all types of SUD treatment at four hospital sites in Norway. The questionnaire data on substance use, pain, and posttraumatic stress symptoms will be combined with retrospective and prospective longitudinal data from high-quality demographic and health registries. The registry data cover, for example, treatment episodes, diagnoses, and prescribed medications and socioeconomic variables, with a follow-up period of altogether 20 years (approximately 2008-2029). Results: Questionnaire data were collected during March 2021-June 2024. Altogether 1890 patients were approached, and 1645 (87%) questionnaires were completed. The estimated final sample size pending data cleaning (eg, removal of duplicates and validation of consent forms) is 1400-1500. Linkage of registry data for approximately 1000 with valid ID numbers and consent is planned for 2026 (retrospective) and 2029/2030 (prospective). At least 10 publications are planned in the period 2025-2028, based on funding received from the Foundation Dam, the Norwegian Research Council, Akershus University Hospital, and Oslo University Hospital. We plan to apply for further funding related to the use of the prospective registry data. Conclusions: Results from the NOR-APT study will contribute to a better understanding of SUD, chronic pain and PTSD comorbidities, their interactions, trajectories and impact on SUD treatment outcomes, and subjective quality of life. Results can also contribute knowledge toward the development and assessment of treatment interventions that can improve SUD treatment outcomes. Trial Registration: ClinicalTrials.gov NCT04908410; https://clinicaltrials.gov/study/NCT04908410 International Registered Report Identifier (IRRID): DERR1-10.2196/67663
- Open Access
Impact of dextroamphetamine substitution on the use of illicit amphetamines in adults with amphetamine dependence: a study protocol for the multicentre double blind randomised controlled trial ATLAS4Dependence
Introduction: There is limited evidence on how to effectively treat individuals from marginalised populations with dependence on amphetamine and/or methamphetamine (collectively referred to hereafter as amphetamine dependence). The disease burden is extremely high in this population, especially related to psychiatric comorbidities, cardiovascular complications, injection-related infections and poor social functioning. ATLAS4Dependence is a multi-centre randomised, placebo-controlled, double-blind trial that will investigate the effectiveness and safety of substitution treatment with dextroamphetamine compared with placebo in people with amphetamine dependence. Methods and analysis: The trial will recruit 226 adult patients in several outpatient clinics in Norway. Inclusion criteria comprise individuals with amphetamine dependence, defined as use on three or more days per week during the past 28 days, who currently inject or have formerly injected drugs. This includes individuals both with and without comorbid opioid dependence, as well as those currently receiving or not receiving opioid agonist treatment. Participants will be randomly assigned 1:1 to receive either dextroamphetamine or placebo for 12 weeks. Flexible doses within the range of 30–120 mg daily will be provided based on individual assessments. The participants in both arms will be offered standard psychosocial and medical follow-up in accordance with current clinical practice. The endpoint assessments will be conducted at 12 weeks with weekly self-reports and safety assessments and a follow-up assessment at 52 weeks. The primary objective of the study is to assess the impact of 12 weeks daily prescribed oral dextroamphetamine versus placebo on the use of illicit amphetamines as well as on the total amount of amphetamines used (including both illicit and prescribed sources). Secondary outcomes are the differences between the groups at 12 weeks regarding psychological distress, symptoms of psychosis, quality of life, cardiovascular risk factors, injection-related infections, executive functioning, attention-deficit hyperactivity disorder-related symptoms, sleep, violence risk, fatigue, symptoms of craving and withdrawal, treatment retention, days of use of illicit amphetamines and use at 4 weeks and 8 weeks during the intervention period, use of other illicit substances and alcohol, as well as a cost-effectiveness analysis (using private economy, criminal activity and health service utilisation) and a qualitative approach to assess overall experiences with the study intervention. Analysis and reporting will follow the Consolidated Standards of Reporting Trials guidelines. All tests will be two-sided. Descriptive results and the estimated effectiveness will be presented with 95% CIs. The difference between the groups at the primary time point (at the end of the 12-week trial) will be assessed using χ 2 test (for use of illicit amphetamines measured by monthly urine tests) and Analysis of Covariance (ANCOVA) (for weekly self-reported total amount of amphetamines). Analyses for the primary endpoint will be undertaken on an intention-to-treat basis and reported on as such, but sensitivity analyses with per protocol analyses will also be presented. Ethics and dissemination: The study is approved by European Medicines Agency, Clinical Trial Information System (CTIS). Written informed consent will be obtained from all patients. Study results will be published in international peer-reviewed medical journals. Trial registration number: CTIS 2023-510404-44-00.
Open AccessImpact of dextroamphetamine substitution on the use of illicit amphetamines in adults with amphetamine dependence: a study protocol for the multicentre double blind randomised controlled trial ATLAS4Dependence
Introduction: There is limited evidence on how to effectively treat individuals from marginalised populations with dependence on amphetamine and/or methamphetamine (collectively referred to hereafter as amphetamine dependence). The disease burden is extremely high in this population, especially related to psychiatric comorbidities, cardiovascular complications, injection-related infections and poor social functioning. ATLAS4Dependence is a multi-centre randomised, placebo-controlled, double-blind trial that will investigate the effectiveness and safety of substitution treatment with dextroamphetamine compared with placebo in people with amphetamine dependence. Methods and analysis: The trial will recruit 226 adult patients in several outpatient clinics in Norway. Inclusion criteria comprise individuals with amphetamine dependence, defined as use on three or more days per week during the past 28 days, who currently inject or have formerly injected drugs. This includes individuals both with and without comorbid opioid dependence, as well as those currently receiving or not receiving opioid agonist treatment. Participants will be randomly assigned 1:1 to receive either dextroamphetamine or placebo for 12 weeks. Flexible doses within the range of 30–120 mg daily will be provided based on individual assessments. The participants in both arms will be offered standard psychosocial and medical follow-up in accordance with current clinical practice. The endpoint assessments will be conducted at 12 weeks with weekly self-reports and safety assessments and a follow-up assessment at 52 weeks. The primary objective of the study is to assess the impact of 12 weeks daily prescribed oral dextroamphetamine versus placebo on the use of illicit amphetamines as well as on the total amount of amphetamines used (including both illicit and prescribed sources). Secondary outcomes are the differences between the groups at 12 weeks regarding psychological distress, symptoms of psychosis, quality of life, cardiovascular risk factors, injection-related infections, executive functioning, attention-deficit hyperactivity disorder-related symptoms, sleep, violence risk, fatigue, symptoms of craving and withdrawal, treatment retention, days of use of illicit amphetamines and use at 4 weeks and 8 weeks during the intervention period, use of other illicit substances and alcohol, as well as a cost-effectiveness analysis (using private economy, criminal activity and health service utilisation) and a qualitative approach to assess overall experiences with the study intervention. Analysis and reporting will follow the Consolidated Standards of Reporting Trials guidelines. All tests will be two-sided. Descriptive results and the estimated effectiveness will be presented with 95% CIs. The difference between the groups at the primary time point (at the end of the 12-week trial) will be assessed using χ 2 test (for use of illicit amphetamines measured by monthly urine tests) and Analysis of Covariance (ANCOVA) (for weekly self-reported total amount of amphetamines). Analyses for the primary endpoint will be undertaken on an intention-to-treat basis and reported on as such, but sensitivity analyses with per protocol analyses will also be presented. Ethics and dissemination: The study is approved by European Medicines Agency, Clinical Trial Information System (CTIS). Written informed consent will be obtained from all patients. Study results will be published in international peer-reviewed medical journals. Trial registration number: CTIS 2023-510404-44-00.
- Open Access
- 10 October 2025
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 276, 112917
Changes in quality of life during 52 weeks of extended-release naltrexone treatment, subsequent by a 1-year post-treatment period
- 10 October 2025
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 276, 112917
Open AccessChanges in quality of life during 52 weeks of extended-release naltrexone treatment, subsequent by a 1-year post-treatment period
- Open Access
- 23 September 2025
- Published by Center for Open Science in PsyArXiv
Experimental Pain Responses and Clinical Pain Symptoms in Patients Receiving Opioid Agonist and Antagonist Treatment for Opioid Use Disorder: An Observational Study
Background. Opioid use disorder (OUD) treatment mainly involves long-term use of medications that either stimulate (agonists) or block (antagonists) mu-opioid receptors and that could potentially affect patients’ experiences of pain. We therefore conducted an observational study of pain symptoms and sensitivity in patients receiving opioid agonist and antagonist treatment for OUD, and healthy volunteers.Methods. Seventy-four OUD patients receiving the antagonist extended-release naltrexone (XR-NTX; n = 34) or opioid agonists (methadone or buprenorphine; n = 40), as well as 50 healthy volunteers participated in a single study session. Participants answered questions about their current pain symptoms, and completed a Cold Pressor Test (CPT) while we measured heart rate and salivary cortisol. Hypotheses and analyses were preregistered before data access. Group differences in chronic pain rates and cold pain responses were modeled with logistic, beta and linear regression and tested with likelihood ratio χ2- and F-tests.Results. Half of patients in either treatment reported living with chronic pain. Individual CPT responses were variable. Patients on opioid agonists and XR-NTX reported pain 2 and 9 seconds earlier than and removed their hand 34 and 46 seconds before healthy volunteers. These group differences align with prior findings of heightened pain sensitivity in agonist-maintained patients but were non-significant (ps = 1). Differences in cold pain intensity and cold pain-induced changes in heart rate and cortisol aligned with hypotheses but were also non-significant (ps ≥ 0.17). Conclusion. Consistent with prior observations, the current findings indicate that a considerable number of OUD patients experience persistent pain symptoms while undergoing either opioid agonists or XR-NTX treatment. Major detrimental or beneficial effects of these medications on pain and pain sensitivity seem unlikely however.
- 23 September 2025
- Published by Center for Open Science in PsyArXiv
Open AccessExperimental Pain Responses and Clinical Pain Symptoms in Patients Receiving Opioid Agonist and Antagonist Treatment for Opioid Use Disorder: An Observational Study
Background. Opioid use disorder (OUD) treatment mainly involves long-term use of medications that either stimulate (agonists) or block (antagonists) mu-opioid receptors and that could potentially affect patients’ experiences of pain. We therefore conducted an observational study of pain symptoms and sensitivity in patients receiving opioid agonist and antagonist treatment for OUD, and healthy volunteers.Methods. Seventy-four OUD patients receiving the antagonist extended-release naltrexone (XR-NTX; n = 34) or opioid agonists (methadone or buprenorphine; n = 40), as well as 50 healthy volunteers participated in a single study session. Participants answered questions about their current pain symptoms, and completed a Cold Pressor Test (CPT) while we measured heart rate and salivary cortisol. Hypotheses and analyses were preregistered before data access. Group differences in chronic pain rates and cold pain responses were modeled with logistic, beta and linear regression and tested with likelihood ratio χ2- and F-tests.Results. Half of patients in either treatment reported living with chronic pain. Individual CPT responses were variable. Patients on opioid agonists and XR-NTX reported pain 2 and 9 seconds earlier than and removed their hand 34 and 46 seconds before healthy volunteers. These group differences align with prior findings of heightened pain sensitivity in agonist-maintained patients but were non-significant (ps = 1). Differences in cold pain intensity and cold pain-induced changes in heart rate and cortisol aligned with hypotheses but were also non-significant (ps ≥ 0.17). Conclusion. Consistent with prior observations, the current findings indicate that a considerable number of OUD patients experience persistent pain symptoms while undergoing either opioid agonists or XR-NTX treatment. Major detrimental or beneficial effects of these medications on pain and pain sensitivity seem unlikely however.
- Open Access
- 30 June 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Chronic Pain and Posttraumatic Stress Among Patients in Substance Use Treatment: Protocol for NOR-APT, a Longitudinal Cohort Study (Preprint)
BACKGROUND Chronic pain conditions and posttraumatic stress disorder (PTSD) are highly prevalent among patients with substance use disorders (SUDs). Both can impact outcomes of SUD treatment and quality of life. There is a need for a large-scale study on the overlap of and interactions between SUD, chronic pain, and PTSD. OBJECTIVE The Norwegian Addiction, Pain and Trauma study (NOR-APT) is the first longitudinal study to describe how substance use and outcomes of SUD treatment are impacted by (1) chronic pain and pain characteristics and (2) interactions between comorbid chronic pain and PTSD. METHODS Self-reported questionnaire data were collected from patients in all types of SUD treatment at four hospital sites in Norway. The questionnaire data on substance use, pain, and posttraumatic stress symptoms will be combined with retrospective and prospective longitudinal data from high-quality demographic and health registries. The registry data cover, for example, treatment episodes, diagnoses, and prescribed medications and socioeconomic variables, with a follow-up period of altogether 20 years (approximately 2008-2029). RESULTS Questionnaire data were collected during March 2021-June 2024. Altogether 1890 patients were approached, and 1645 (87%) questionnaires were completed. The estimated final sample size pending data cleaning (eg, removal of duplicates and validation of consent forms) is 1400-1500. Linkage of registry data for approximately 1000 with valid ID numbers and consent is planned for 2026 (retrospective) and 2029/2030 (prospective). At least 10 publications are planned in the period 2025-2028, based on funding received from the Foundation Dam, the Norwegian Research Council, Akershus University Hospital, and Oslo University Hospital. We plan to apply for further funding related to the use of the prospective registry data. CONCLUSIONS Results from the NOR-APT study will contribute to a better understanding of SUD, chronic pain and PTSD comorbidities, their interactions, trajectories and impact on SUD treatment outcomes, and subjective quality of life. Results can also contribute knowledge toward the development and assessment of treatment interventions that can improve SUD treatment outcomes. CLINICALTRIAL ClinicalTrials.gov NCT04908410; https://clinicaltrials.gov/study/NCT04908410 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/67663
- 30 June 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessChronic Pain and Posttraumatic Stress Among Patients in Substance Use Treatment: Protocol for NOR-APT, a Longitudinal Cohort Study (Preprint)
BACKGROUND Chronic pain conditions and posttraumatic stress disorder (PTSD) are highly prevalent among patients with substance use disorders (SUDs). Both can impact outcomes of SUD treatment and quality of life. There is a need for a large-scale study on the overlap of and interactions between SUD, chronic pain, and PTSD. OBJECTIVE The Norwegian Addiction, Pain and Trauma study (NOR-APT) is the first longitudinal study to describe how substance use and outcomes of SUD treatment are impacted by (1) chronic pain and pain characteristics and (2) interactions between comorbid chronic pain and PTSD. METHODS Self-reported questionnaire data were collected from patients in all types of SUD treatment at four hospital sites in Norway. The questionnaire data on substance use, pain, and posttraumatic stress symptoms will be combined with retrospective and prospective longitudinal data from high-quality demographic and health registries. The registry data cover, for example, treatment episodes, diagnoses, and prescribed medications and socioeconomic variables, with a follow-up period of altogether 20 years (approximately 2008-2029). RESULTS Questionnaire data were collected during March 2021-June 2024. Altogether 1890 patients were approached, and 1645 (87%) questionnaires were completed. The estimated final sample size pending data cleaning (eg, removal of duplicates and validation of consent forms) is 1400-1500. Linkage of registry data for approximately 1000 with valid ID numbers and consent is planned for 2026 (retrospective) and 2029/2030 (prospective). At least 10 publications are planned in the period 2025-2028, based on funding received from the Foundation Dam, the Norwegian Research Council, Akershus University Hospital, and Oslo University Hospital. We plan to apply for further funding related to the use of the prospective registry data. CONCLUSIONS Results from the NOR-APT study will contribute to a better understanding of SUD, chronic pain and PTSD comorbidities, their interactions, trajectories and impact on SUD treatment outcomes, and subjective quality of life. Results can also contribute knowledge toward the development and assessment of treatment interventions that can improve SUD treatment outcomes. CLINICALTRIAL ClinicalTrials.gov NCT04908410; https://clinicaltrials.gov/study/NCT04908410 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/67663
- 28 April 2025
- Published by Wiley in The American Journal on Addictions
Pain intensity in patients using extended‐release naltrexone or opioid agonists and its effect on extended‐release naltrexone treatment outcomes
Background and Objectives: Extended‐release naltrexone (XR‐NTX) is an opioid antagonist effective for treating opioid use disorder (OUD). However, concerns about inadequate pain management may limit its use. This study will examine changes in pain intensity in OUD patients choosing XR‐NTX compared to opioid agonist treatment (OAT), identify subgroups with distinct pain intensity trajectories, and assess the effect of pain intensity on XR‐NTX treatment outcomes (retention, relapse, opioid use, and cravings).Methods: This 24‐week study included OUD patients aged 18–65 years opting for XR‐NTX (n = 160). Patients receiving OAT (n = 151) served as controls. Pain intensity was measured every 4 weeks for XR‐NTX and at baseline and Week 24 for OAT using the numerical pain rating scale‐11 (NPRS‐11). Data were analyzed with linear mixed models and group‐based trajectory modeling.Results: Between baseline and Week 24, XR‐NTX participants with low to moderate pain showed a significant reduction in pain intensity, while those with high pain did not. In the OAT group, no significant reduction in pain intensity was observed (from baseline to Week 24). Pain intensity was not associated with XR‐NTX treatment outcomes.Discussion and Conclusions: Contrary to perception, XR‐NTX does not worsen pain intensity, nor did pain intensity affect XR‐NTX treatment outcomes.Scientific Significance: This study is the first to explore the association between changes in pain intensity and XR‐NTX treatment outcomes in OUD patients over a 24‐week period. The findings challenge the perception that XR‐NTX is less suitable for treating OUD patients with pain.
- 28 April 2025
- Published by Wiley in The American Journal on Addictions
Pain intensity in patients using extended‐release naltrexone or opioid agonists and its effect on extended‐release naltrexone treatment outcomes
Background and Objectives: Extended‐release naltrexone (XR‐NTX) is an opioid antagonist effective for treating opioid use disorder (OUD). However, concerns about inadequate pain management may limit its use. This study will examine changes in pain intensity in OUD patients choosing XR‐NTX compared to opioid agonist treatment (OAT), identify subgroups with distinct pain intensity trajectories, and assess the effect of pain intensity on XR‐NTX treatment outcomes (retention, relapse, opioid use, and cravings).Methods: This 24‐week study included OUD patients aged 18–65 years opting for XR‐NTX (n = 160). Patients receiving OAT (n = 151) served as controls. Pain intensity was measured every 4 weeks for XR‐NTX and at baseline and Week 24 for OAT using the numerical pain rating scale‐11 (NPRS‐11). Data were analyzed with linear mixed models and group‐based trajectory modeling.Results: Between baseline and Week 24, XR‐NTX participants with low to moderate pain showed a significant reduction in pain intensity, while those with high pain did not. In the OAT group, no significant reduction in pain intensity was observed (from baseline to Week 24). Pain intensity was not associated with XR‐NTX treatment outcomes.Discussion and Conclusions: Contrary to perception, XR‐NTX does not worsen pain intensity, nor did pain intensity affect XR‐NTX treatment outcomes.Scientific Significance: This study is the first to explore the association between changes in pain intensity and XR‐NTX treatment outcomes in OUD patients over a 24‐week period. The findings challenge the perception that XR‐NTX is less suitable for treating OUD patients with pain.
- Open Access
- 28 March 2025
- Published by Center for Open Science in OSF Preprints
Reward Sensitivity in Patients Receiving Opioid Agonist and Antagonist Treatment for Opioid Use Disorder: An Observational Study
Background. Disrupted reward processing is a core component in neurobiological theories of addictions, including opioid use disorder (OUD). While acute opioid agonist and antagonist administration can modulate reward behavior and experiences, it remains unclear how typical long-term OUD treatment with these medications impact patients’ sensitivity to substance-free rewards. We therefore conducted a cross-sectional study of reward sensitivity in opioid agonist- and antagonist-treated OUD patients, and healthy volunteers.Methods. Ninety-six OUD patients on extended-release naltrexone (n=45) or opioid agonists (n=51) and 50 healthy volunteers completed a probabilistic reward task (PRT) and self-report measures of anhedonia, depression, preoccupation with immediate consequences, substance craving and life satisfaction in a single session. We used signal detection analysis and drift diffusion modeling to derive behavioral reward bias measures from PRT performance. Group differences were modeled with beta and linear regression.Results. Patients reported significantly greater anhedonia (Cohen’s ds≥0.64), depression (ds≥0.53) and preoccupation with immediate consequences (ds≥0.54) than heathy volunteers, but differences between naltrexone- and opioid agonist-treated patients were non-significant (ds≤0.26). Group differences in behavioral reward bias were small and non-significant (ps=1, BF01s≥84.13). Anhedonia was significantly associated with lower life satisfaction (OR [95% CI]=1.10 [1.04, 1.17]). There were no other significant associations between reward sensitivity measures and life satisfaction or craving (ps≥0.31, BF01s≥2.58).Conclusion. These data support an association between OUD and reduced well-being irrespective of opioid agonist or antagonist treatment, highlighting patients’ need for psychosocial support and/or adjunct interventions. Major detrimental effects of naltrexone treatment on well-being seem unlikely from these and previous results.
- 28 March 2025
- Published by Center for Open Science in OSF Preprints
Open AccessReward Sensitivity in Patients Receiving Opioid Agonist and Antagonist Treatment for Opioid Use Disorder: An Observational Study
Background. Disrupted reward processing is a core component in neurobiological theories of addictions, including opioid use disorder (OUD). While acute opioid agonist and antagonist administration can modulate reward behavior and experiences, it remains unclear how typical long-term OUD treatment with these medications impact patients’ sensitivity to substance-free rewards. We therefore conducted a cross-sectional study of reward sensitivity in opioid agonist- and antagonist-treated OUD patients, and healthy volunteers.Methods. Ninety-six OUD patients on extended-release naltrexone (n=45) or opioid agonists (n=51) and 50 healthy volunteers completed a probabilistic reward task (PRT) and self-report measures of anhedonia, depression, preoccupation with immediate consequences, substance craving and life satisfaction in a single session. We used signal detection analysis and drift diffusion modeling to derive behavioral reward bias measures from PRT performance. Group differences were modeled with beta and linear regression.Results. Patients reported significantly greater anhedonia (Cohen’s ds≥0.64), depression (ds≥0.53) and preoccupation with immediate consequences (ds≥0.54) than heathy volunteers, but differences between naltrexone- and opioid agonist-treated patients were non-significant (ds≤0.26). Group differences in behavioral reward bias were small and non-significant (ps=1, BF01s≥84.13). Anhedonia was significantly associated with lower life satisfaction (OR [95% CI]=1.10 [1.04, 1.17]). There were no other significant associations between reward sensitivity measures and life satisfaction or craving (ps≥0.31, BF01s≥2.58).Conclusion. These data support an association between OUD and reduced well-being irrespective of opioid agonist or antagonist treatment, highlighting patients’ need for psychosocial support and/or adjunct interventions. Major detrimental effects of naltrexone treatment on well-being seem unlikely from these and previous results.
- Open Access
- 21 February 2025
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 152, 107861
Changes in mental health during long-term treatment with extended-release naltrexone: A 3-year clinical study of opioid dependent individuals
- 21 February 2025
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 152, 107861
Open AccessChanges in mental health during long-term treatment with extended-release naltrexone: A 3-year clinical study of opioid dependent individuals